AFT Pharmaceuticals (ASX:AFP) Change In Receivables: A$0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:AFP AFT Pharmaceuticals Ltd ASX:AFP
90 GF Score
Price A$3.19
GF Value A$3.39
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is AFT Pharmaceuticals Change In Receivables?

AFT Pharmaceuticals ASX:AFP 90 Change In Receivables is A$0.0 Mil as of Mar. 2026. GuruFocus rates ASX:AFP with a GF Score™ of 90/100 and a GF Value™ of A$3.39 (Fairly Valued). The stock has 4 warning signs investors should review.

AFT Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2026 was A$0.0 Mil. It means AFT Pharmaceuticals's Accounts Receivable stayed the same from Sep. 2025 to Mar. 2026 .

AFT Pharmaceuticals's change in receivables for the fiscal year that ended in Mar. 2026 was A$0.0 Mil. It means AFT Pharmaceuticals's Accounts Receivable stayed the same from Mar. 2025 to Mar. 2026 .

AFT Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2026 was A$61.3 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. AFT Pharmaceuticals's Days Sales Outstanding for the six months ended in Mar. 2026 was 97.54.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. AFT Pharmaceuticals's liquidation value for the six months ended in Mar. 2026 was A$-4.6 Mil.

AFT Pharmaceuticals  (ASX:AFP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

AFT Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=61.321/114.733*91
=97.54

2. In Ben Graham's calculation of liquidation value, AFT Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

AFT Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=8.533-89.951+0.75 * 61.321+0.5 * 61.722
=-4.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AFT Pharmaceuticals Change In Receivables Related Terms

AFT Pharmaceuticals Change In Receivables Historical Data

* Premium members only.

The historical data trend for AFT Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AFT Pharmaceuticals Change In Receivables Chart

AFT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AFT Pharmaceuticals Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:AFP
90GF Score
AFT Pharmaceuticals Ltd ASX:AFP
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AFT Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of A$0.0 Mil mean?
AFT Pharmaceuticals (ASX:AFP) has a Change In Receivables of A$0.0 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for AFT Pharmaceuticals and its competitors.
Is AFT Pharmaceuticals' Change In Receivables too high?
AFT Pharmaceuticals' current Change In Receivables is A$0.0 Mil. Overall, AFT Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Change In Receivables compare to ZTS and UTHR?
AFT Pharmaceuticals' Change In Receivables of A$0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for AFT Pharmaceuticals and its competitors. AFT Pharmaceuticals's current Change In Receivables is A$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (ASX:AFP) is currently considered Fairly Valued. The stock's GF Value™ is A$3.39, compared to a current price of A$3.19 — trading 5.9% below its estimated fair value. The current Change In Receivables is A$0.0 Mil. AFT Pharmaceuticals' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For AFT Pharmaceuticals (ASX:AFP), the current Change In Receivables is A$0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AFT Pharmaceuticals (ASX:AFP) Overvalued in 2026?

Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued. The current stock price of A$3.19 is trading 5.9% below its estimated GF Value™ of A$3.39. GuruFocus considers AFT Pharmaceuticals to be Fairly Valued.

Key valuation signals for ASX:AFP:

  • Change In Receivables: A$0.0 Mil
  • GF Value™: A$3.39 vs. price of A$3.19 (5.9% below fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the ASX:AFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AFT Pharmaceuticals Business Description

Other Exchanges AFT:New Zealand
Address 129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
90GF Score

Get the complete analysis for ASX:AFP

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$3.19
Price
A$3.39
GF Value